Frequency of anti-VEGF treatment trends toward extended intervals

KOLOA, Hawaii – In 2014, the decision to re-treat patients with age-related macular degeneration with anti-VEGF injections will be based on anatomic changes seen on spectral-domain optical coherence tomography, according to a speaker here.Whether using ranibizumab, bevacizumab or aflibercept,“real-world” treatment intervals will be extended to longer than every 4 weeks based on that data, Elias Reichel, MD, toldcolleaguesat Retina 2014.Reichel said that “in the real world,” physicians are not dosing their patients monthly and following them monthly for 2 years as was done in the CATT study.

Full Story →